Figure 5.

Clinical and molecular evolution of patients receiving a first FGFR inhibitor followed by the irreversible, highly selective FGFR2 inhibitor lirafugratinib. A, Four patients harboring a FGFR2 fusion received lirafugratinib as a second FGFR inhibitor. None received intercurrent treatment between the FGFR inhibitors. B, Clinicoradiologic and molecular evolution of patient ST3470, with a cholangiorcarcinoma driven by FGFR2::BICC1 progressing on pemigatinib. C, Patient MR1271 had duodenal cancer progressing on futibatinib with emergence of FGFR2 V565L mutation that was cleared by lirafugratinib. The ctDNA findings are reported as VAF (%). BOR, best objective response; PD, progressive disease; PR, partial response; SD, stable disease.